| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TALKTalkspace, Inc. | 634.46M | 3.83 | 589.23 | 25.02% | 1.98% | 3.89% | 0.99% | |
| SYRASyra Health Corp. Class A Common Stock | 907.13K | 0.08 | -0.15 | 44.73% | -16.89% | -57.31% | 0.16 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.41M | 5.62M | 5.52M | 7.98M |
| Revenue Growth % | - | - | 2.98% | -0.02% | 0.45% |
| Cost of Goods Sold | 0 | 979.62K | 4.56M | 4.11M | 6.33M |
| COGS % of Revenue | - | 0.69% | 0.81% | 0.74% | 0.79% |
| Gross Profit | 0 | 430.35K | 1.06M | 1.41M | 1.65M |
| Gross Margin % | - | 0.31% | 0.19% | 0.26% | 0.21% |
| Gross Profit Growth % | - | - | 1.47% | 0.33% | 0.17% |
| Operating Expenses | 4.27K | 433.63K | 3.15M | 4.3M | 5.42M |
| OpEx % of Revenue | - | 0.31% | 0.56% | 0.78% | 0.68% |
| Selling, General & Admin | 4.27K | 416.01K | 3.11M | 4.01M | 1.45M |
| SG&A % of Revenue | - | 0.3% | 0.55% | 0.73% | 0.18% |
| Research & Development | 0 | 0 | 0 | 240.05K | 585.15K |
| R&D % of Revenue | - | - | - | 0.04% | 0.07% |
| Other Operating Expenses | 0 | 17.63K | 45.59K | 52.14K | 3.39M |
| Operating Income | -4.27K | -3.28K | -2.09M | -2.89M | -3.76M |
| Operating Margin % | - | -0% | -0.37% | -0.52% | -0.47% |
| Operating Income Growth % | - | 0.23% | -636.1% | -0.38% | -0.3% |
| EBITDA | -4.27K | -3.07K | -2.07M | -2.84M | -3.7M |
| EBITDA Margin % | - | -0% | -0.37% | -0.51% | -0.46% |
| EBITDA Growth % | - | 0.28% | -674.19% | -0.37% | -0.3% |
| D&A (Non-Cash Add-back) | 0 | 207 | 14.85K | 48.77K | 62.74K |
| EBIT | -4.27K | -3.28K | -2.09M | -2.88M | -3.74M |
| Net Interest Income | 0 | 0 | -28.47K | -50.74K | 5.65K |
| Interest Income | 0 | 0 | 63 | 2.94K | 21.25K |
| Interest Expense | 0 | 0 | 28.53K | 53.69K | 15.6K |
| Other Income/Expense | 0 | 0 | -28.47K | -50.74K | 5.65K |
| Pretax Income | -4.27K | -3.28K | -2.12M | -2.94M | -3.76M |
| Pretax Margin % | - | -0% | -0.38% | -0.53% | -0.47% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% |
| Net Income | -4.27K | -3.28K | -2.12M | -2.94M | -3.76M |
| Net Margin % | - | -0% | -0.38% | -0.53% | -0.47% |
| Net Income Growth % | - | 0.23% | -644.78% | -0.39% | -0.28% |
| Net Income (Continuing) | -4.27K | -3.28K | -2.12M | -2.94M | -3.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | -0.00 | -0.29 | -0.60 | -0.52 |
| EPS Growth % | - | - | - | -1.07% | 0.13% |
| EPS (Basic) | -0.00 | -0.00 | -0.36 | -0.60 | -0.52 |
| Diluted Shares Outstanding | 5.98M | 7.28M | 7.28M | 4.88M | 7.26M |
| Basic Shares Outstanding | 5.98M | 7.28M | 5.86M | 4.88M | 7.26M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 3K | 382.14K | 1.43M | 4.78M | 3.35M |
| Cash & Short-Term Investments | 3K | 100.01K | 3.34K | 3.28M | 2.4M |
| Cash Only | 3K | 100.01K | 3.34K | 3.28M | 2.4M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 282.13K | 1.35M | 1.18M | 680.83K |
| Days Sales Outstanding | - | 73.04 | 87.47 | 78.38 | 31.13 |
| Inventory | 0 | 0 | 47.21K | 0 | 0 |
| Days Inventory Outstanding | - | - | 3.78 | - | - |
| Other Current Assets | 0 | 0 | -17.21K | 0 | 276.56K |
| Total Non-Current Assets | 0 | 154.75K | 892.9K | 142.17K | 325.54K |
| Property, Plant & Equipment | 0 | 154.75K | 296.78K | 142.17K | 325.54K |
| Fixed Asset Turnover | - | 9.11x | 18.93x | 38.79x | 24.52x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 596.12K | 0 | 0 |
| Total Assets | 3K | 536.89K | 2.32M | 4.92M | 3.68M |
| Asset Turnover | - | 2.63x | 2.42x | 1.12x | 2.17x |
| Asset Growth % | - | 177.96% | 3.32% | 1.12% | -0.25% |
| Total Current Liabilities | 7.17K | 452.29K | 1.55M | 910.07K | 613.55K |
| Accounts Payable | 0 | 125.73K | 435.59K | 462.99K | 101.69K |
| Days Payables Outstanding | - | 46.85 | 34.9 | 41.15 | 5.86 |
| Short-Term Debt | 3K | 194.2K | 750.55K | 184.9K | 152.89K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 16.61K |
| Other Current Liabilities | -3K | -194.2K | 7.68K | 50.05K | 0 |
| Current Ratio | 0.42x | 0.84x | 0.92x | 5.25x | 5.46x |
| Quick Ratio | 0.42x | 0.84x | 0.89x | 5.25x | 5.46x |
| Cash Conversion Cycle | - | - | 56.35 | - | - |
| Total Non-Current Liabilities | 0 | 91.74K | 63.2K | 0 | 187.21K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 187.21K |
| Capital Lease Obligations | 0 | 91.74K | 63.2K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 7.17K | 544.04K | 1.61M | 910.07K | 800.76K |
| Total Debt | 3K | 342.86K | 934.84K | 248.1K | 452.08K |
| Net Debt | 0 | 242.85K | 931.5K | -3.03M | -1.94M |
| Debt / Equity | - | - | 1.32x | 0.06x | 0.16x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | -73.24x | -53.79x | -241.34x |
| Total Equity | -4.17K | -7.15K | 710.1K | 4.01M | 2.88M |
| Equity Growth % | - | -0.72% | 100.36% | 4.65% | -0.28% |
| Book Value per Share | -0.00 | -0.00 | 0.10 | 0.82 | 0.40 |
| Total Shareholders' Equity | -4.17K | -7.15K | 710.1K | 4.01M | 2.88M |
| Common Stock | 1K | 1K | 4.4K | 6.42K | 9.81K |
| Retained Earnings | -5.17K | -8.45K | -2.13M | -5.06M | -8.82M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | 0 | -88.2K | -2.24M | -2.76M | -2.93M |
| Operating CF Margin % | - | -0.06% | -0.4% | -0.5% | -0.37% |
| Operating CF Growth % | - | - | -24.44% | -0.23% | -0.06% |
| Net Income | -51.2K | -3.28K | -2.12M | -2.94M | -3.76M |
| Depreciation & Amortization | 0 | 207 | 14.85K | 48.77K | 62.74K |
| Stock-Based Compensation | 1.2K | 0 | 2.91K | 32.83K | 59.8K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 27.26K | 619.64K | 121.09K | 160.88K |
| Working Capital Changes | 50K | -112.39K | -763.3K | -23.42K | 543.79K |
| Change in Receivables | 0 | -260.63K | -940.47K | -110.16K | 430.42K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 125.73K | 309.86K | 27.4K | -361.3K |
| Cash from Investing | 0 | -6.29K | -121.26K | -15.25K | -11.11K |
| Capital Expenditures | 0 | -6.29K | -121.26K | -15.25K | -11.11K |
| CapEx % of Revenue | - | 0% | 0.02% | 0% | 0% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 36K | 191.5K | 2.27M | 6.05M | 2.06M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | 36K | 191.2K | -790.32K | 200.01K | 0 |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | 0 | -94.49K | -2.37M | -2.77M | -2.94M |
| FCF Margin % | - | -0.07% | -0.42% | -0.5% | -0.37% |
| FCF Growth % | - | - | -24.03% | -0.17% | -0.06% |
| FCF per Share | - | -0.01 | -0.32 | -0.57 | -0.41 |
| FCF Conversion (FCF/Net Income) | - | 26.89x | 1.06x | 0.94x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 36.23K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -602.65% | -124.42% | -109.09% |
| Return on Invested Capital (ROIC) | - | -2.12% | -166.97% | -165.14% | -294.67% |
| Gross Margin | - | 30.52% | 18.9% | 25.54% | 20.71% |
| Net Margin | - | -0.23% | -37.71% | -53.28% | -47.1% |
| Debt / Equity | - | - | 1.32x | 0.06x | 0.16x |
| Interest Coverage | - | - | -73.24x | -53.79x | -241.34x |
| FCF Conversion | - | 26.89x | 1.06x | 0.94x | 0.78x |
| Revenue Growth | - | - | 298.43% | -1.83% | 44.73% |
| 2023 | 2024 | |
|---|---|---|
| Population Health | 715.5K | 312K |
| Population Health Growth | - | -56.39% |
| Health Education | 12.31K | - |
| Health Education Growth | - | - |
Syra Health Corp. Class A Common Stock (SYRA) reported $7.5M in revenue for fiscal year 2024.
Syra Health Corp. Class A Common Stock (SYRA) grew revenue by 44.7% over the past year. This is strong growth.
Syra Health Corp. Class A Common Stock (SYRA) reported a net loss of $1.3M for fiscal year 2024.
Syra Health Corp. Class A Common Stock (SYRA) has a return on equity (ROE) of -109.1%. Negative ROE indicates the company is unprofitable.
Syra Health Corp. Class A Common Stock (SYRA) had negative free cash flow of $0.2M in fiscal year 2024, likely due to heavy capital investments.